These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12559512)

  • 41. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up.
    Buttinelli C; Clemenzi A; Borriello G; Denaro F; Pozzilli C; Fieschi C
    Eur J Neurol; 2007 Nov; 14(11):1281-7. PubMed ID: 17956449
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.
    Hartung HP; Gonsette R; König N; Kwiecinski H; Guseo A; Morrissey SP; Krapf H; Zwingers T;
    Lancet; 2002 Dec 21-28; 360(9350):2018-25. PubMed ID: 12504397
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
    Krapf H; Morrissey SP; Zenker O; Zwingers T; Gonsette R; Hartung HP;
    Neurology; 2005 Sep; 65(5):690-5. PubMed ID: 16157900
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
    Pascual AM; Téllez N; Boscá I; Mallada J; Belenguer A; Abellán I; Sempere AP; Fernández P; Magraner MJ; Coret F; Sanz MA; Montalbán X; Casanova B
    Mult Scler; 2009 Nov; 15(11):1303-10. PubMed ID: 19825889
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.
    Stüve O; Kita M; Pelletier D; Fox RJ; Stone J; Goodkin DE; Zamvil SS
    Mult Scler; 2004 Jun; 10 Suppl 1():S58-61. PubMed ID: 15218811
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The current role of mitoxantrone in the treatment of multiple sclerosis.
    Cocco E; Marrosu MG
    Expert Rev Neurother; 2014 Jun; 14(6):607-16. PubMed ID: 24834466
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.
    Le Page E; Deburghgraeve V; Lester MA; Cardiet I; Leray E; Edan G
    J Neurol; 2015; 262(4):1024-34. PubMed ID: 25701008
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
    Arnold DL; Campagnolo D; Panitch H; Bar-Or A; Dunn J; Freedman MS; Gazda SK; Vollmer T
    J Neurol; 2008 Oct; 255(10):1473-8. PubMed ID: 18854910
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mitoxantrone reduced disability in Iranian patients with multiple sclerosis.
    Hamzehloo A; Etemadifar M
    Arch Iran Med; 2007 Jan; 10(1):59-64. PubMed ID: 17198456
    [TBL] [Abstract][Full Text] [Related]  

  • 52. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multiple sclerosis in Pakistan.
    Wasay M; Ali S; Khatri IA; Hassan A; Asif M; Zakiullah N; Ahmed A; Malik A; Khealani B; Haq A; Fredrikson S
    Mult Scler; 2007 Jun; 13(5):668-9. PubMed ID: 17548448
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study.
    Perini P; Calabrese M; Tiberio M; Ranzato F; Battistin L; Gallo P
    J Neurol; 2006 Aug; 253(8):1034-40. PubMed ID: 16609811
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators.
    Noseworthy JH; Wolinsky JS; Lublin FD; Whitaker JN; Linde A; Gjorstrup P; Sullivan HC
    Neurology; 2000 May; 54(9):1726-33. PubMed ID: 10802775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stability of cognitive functions under mitoxantrone therapy in patients with progressive multiple sclerosis: a pilot analysis.
    Schröder A; Klotz P; Lee DH; Gold R; Linker RA
    Clin Neurol Neurosurg; 2011 Sep; 113(7):527-30. PubMed ID: 21429658
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?
    Ellis R; Brown S; Boggild M
    Mult Scler; 2015 Apr; 21(5):642-5. PubMed ID: 25013152
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Treatment of progressive forms of multiple sclerosis].
    Edan G
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1008-13. PubMed ID: 11787331
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Results of a multicenter study of Rebif-22 mcg administration in Russia].
    Zavalishin IA; Gusev EI; Iakhno NN; Skoromets AA; Boĭko AN; Demina TL; Burlutskiĭ A P ; Beĭn BN; Sholomov II; Pereserdova AV; Stoĭda NI; Zakharova MN; Adarcheva LS; Niiazbekova AS; Askarova LSh; Oleĭnikov VG; Rebrova OIu; Shmidt TE; Davydovskaia MV; Totolian NA; Beskhmel'nitsina IA; Bragina OV; Ponomareva GL; Durseneva OM; Voronchikhina SA; Volkova LI; Turova EL; Streknev AG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):73-8. PubMed ID: 12938639
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mitoxantrone for multiple sclerosis in clinical practice.
    Rizvi SA; Zwibel H; Fox EJ
    Neurology; 2004 Dec; 63(12 Suppl 6):S25-7. PubMed ID: 15623666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.